In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss summertime illnesses and key insights from a recent diagnostic investment event. Together, they explore:

Common summertime illnesses, along with tips for prevention.

• How investment in diagnostic tools influences innovation in the laboratory.
• The potential impact of growing interest in AI investments.
• The investment interest in liquid biopsy and its potential implications for clinical decision-making.
• How AI development may accelerate adoption of mass spectrometry, proteomics, and similar advancements in clinical laboratories.

Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing patients' enhanced risk for pancreatic cancer.

Speaker 4: (00:32)
Could you both please tell us a little bit about yourself and your background?

Speaker 4: (02:23)
Could you please give the audience a brief overview of this assay?

Speaker 4: (03:53)
Which patients should have this test, and when should it be performed?

Speaker 4: (04:49)
What alternative testing options are available, and how do these compare to the new, expanded panel that we're going to be offering?

Speaker 4: (08:20)

How are the results used in patient care?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, share insights from industry news and recent conferences, including PlatforMed. They explore:

• The significant interest in diagnostics for the advancement of cancer care.
• The Joint Commission’s collaboration with the Coalition for Health AI to establish guidelines for the responsible use of artificial intelligence.
• The growing understanding that platforms offer an opportunity to expand access and make knowledge more accessible as platform-driven solutions become a reality.
• The role of laboratorians in guiding the ethical and effective use of data and emerging technologies — and what this means for educating future healthcare professionals.
• The critical importance of values and ethics in deploying new tools.